Delving into the Latest Updates on Anisodamine Hydrobromide with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

mAChRs

Action

antagonists

Mechanism

mAChRs antagonists(Muscarinic acetylcholine receptor antagonists)

Therapeutic Areas

Infectious DiseasesNervous System DiseasesDigestive System Disorders+ [2]

Active Indication

GastrospasmShock, SepticVertigo

Inactive Indication-

Originator Organization

Chengdu First Pharmaceutical Co. Ltd.

Active Organization

Yichang Humanwell Pharmaceuticals Co., Ltd.

Tianjin Jinyao Pharmaceutical Co., Ltd.

Chengdu First Pharmaceutical Co. Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

China (01 Jan 1981),

GastrospasmShock, SepticVertigo

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC17H23NO4

InChIKeyWTQYWNWRJNXDEG-RBZJEDDUSA-N

CAS Registry55869-99-3

View All Structures (2)

AbstractThis study aimed to elucidate the mechanism that total alkaloids in Anisodus tanguticus (AT)(Maxim.) Pascher played anti‐inflammatory and analgesic effects. In this paper, the anti‐inflammatory effect in the total alkaloids of AT was confirmed via lipopolysaccharide (LPS)‐induced inflammation model in RAW 264.7 cells and the main components of AT were immediately analyzed by UPLC/MS. Disease targets were obtained in GeneCards and DisGeNET. Targets of major compounds were searched in ETCM, TCMSP and other databases. The protein‐protein interaction (PPI) network was constructed using STRING database, and Cytoscape was used for core targets screening. GO and KEGG enrichment analysis were performed using Daivid database. Sailvina was used for molecular docking. Molecular dynamics simulation analysis was performed using the Amber 20 program. The results showed that the main components in AT were anisodamine, atropine, fabiatrin, scopolamine, scopoletin and scopolin, possibly exerting anti‐inflammatory and analgesic effects through pathways such as EGFR tyrosine kinase inhibitor resistance and IL‐17 signaling pathway. Fabiatrin and scopolin could be potential drugs with good anti‐inflammatory and analgesic effects.

01 Jan 2025·Food Chemistry

Dual-functional probe-based multi-signal immunosensor platform for tropane alkaloids: Verification and evaluation

Article

Author: Jiang, Haiyang ; Wang, Zile ; Han, Ke ; Zhang, Shuai ; Feng, Zhiyue ; Wang, Sihan ; Sun, Boyan

This study aims to realise rapid detecting of tropane alkaloids (TAs) in food. For this purpose, a broad-spectrum single-chain fragment variable was fused with horseradish peroxidase to create an antibody-enzyme complex (AEC) with antigen recognition and catalytic activity. A multi-signal immunosensor platform based on AEC in the direct competitive reaction mode was constructed using 3,3',5,5'-tetramethylbenzidine and 10-acetyl-3,7-dihydroxyphenoxazine as substrates. The sensitivity of TAs in the immunosensor platform ranged from 0.25 μg/kg to 7912.46 μg/kg. Honey was selected as a representative food sample, and the limit of detection of TAs in honey ranged from 0.02 μg/kg to 409.11 μg/kg, with a recovery rate of 65.7 %-117.1 % and a coefficient of variation less than 21.4 %. Results showed that the immunosensor platform possesses satisfactory accuracy and precision, which highlights its potential for practical applications and its suitability as an ideal tool for rapid screening of TAs in food.

01 Jan 2025·Ecotoxicology and Environmental Safety

Anisodamine ameliorates crystalline silica-exposed pulmonary inflammation and fibrosis via the α7nAChR/JAK2/STAT3 signaling pathway

Article

Author: Ding, Xiaorui ; Liu, Hui ; Kong, Xiaomei ; Liu, Meng ; Wu, Juan ; Xing, Puhua ; Kang, Hong ; Wei, Yangyang

Silicosis is a systemic disease marked by diffuse pulmonary fibrosis resulting from prolonged inhalation of crystalline silica (CS) dust. This study aimed to examine the effects of anisodamine (ANI) on pulmonary inflammation and fibrosis in silicosis, as well as to elucidate the underlying molecular mechanisms. Animal experiments demonstrated that ANI significantly reduced alveolar structure damage and the formation of silicosis nodules in affected mice, as confirmed by pathological slides. ANI inhibited the expression of tumor necrosis factor (TNF-α) in bronchoalveolar lavage fluid (BALF) while promoting the secretion of interleukin-4 (IL-4) and interleukin-10 (IL-10). Further molecular investigations indicated a strong link between pulmonary inflammation and fibrosis, showing decreased levels of α7nAChR and increased expression of phosphorylated Janus kinase 2 (JAK2) and phosphorylated transcription factor 3 (STAT3) in the lung tissues of mice exposed to CS. The relevant molecular alterations in the lung tissue of the model group of mice were reversed by ANI. Methyllycaconitine(MLA, α7nAChR inhibitor) and RO8191 (JAK2/STAT3 agonist) could reverse the therapeutic effect of ANI in silicosis and related molecular mechanisms. The results suggest that ANI may alleviate silicosis by inhibiting pulmonary inflammation and fibrosis through modulation of the JAK2/STAT3 signaling pathway, which is mediated by α7nAChR. Coal workers can utilize ANI early on to treat and prevent silicosis.

100 Deals associated with Anisodamine Hydrobromide

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Anisodamine Hydrobromide	V	DB11785

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Gastrospasm	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Gastrospasm	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Gastrospasm	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Shock, Septic	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Vertigo	China	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981
Vertigo	China	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Vertigo	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02442440 (Pubmed \| Crit Care)	Phase 1/2	Shock, Septic	469	anisodamine (Usual care)	ugvlfkihqm(wgbbhasbul): OR = 0.84 (95% CI, 0.5 - 0.93)	Negative	27 Sep 2021
				Anisodamine